title: Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
abstract: Tirapazamine (TPZ), a bioreductive drug with selective toxicity for hypoxic cells in tumors, is currently in Phase III clinical trials. It has been suggested to have a dual mechanism of action, both generating DNA radicals and oxidizing these radicals to form DNA breaks; whether the second (radical oxidation) step is rate-limiting in cells is not known. In this study we exploit the DNA radical oxidizing ability of the 1-N-oxide metabolite of TPZ, SR 4317, to address this question. SR 4317 at high, but nontoxic, concentrations potentiated the hypoxic (but not aerobic) cytotoxicity of TPZ in all four of the human tumor cell lines tested (HT29, SiHa, FaDu, and A549), thus providing a 2-3-fold increase in the hypoxic cytotoxicity ratio. In potentiating TPZ, SR 4317 was 20-fold more potent than the hypoxic cell radiosensitizers misonidazole and metronidazole but was less potent than misonidazole as a radiosensitizer, suggesting that the initial DNA radicals from TPZ and radiation are different. SR 4317 had favorable pharmacokinetic properties in CD-1 nude mice; coadministration with TPZ provided a large increase in the SR 4317 plasma concentrations relative to that for endogenous SR 4317 from TPZ. It also showed excellent extravascular transport properties in oxic and anoxic HT29 multicellular layers (diffusion coefficient 3 x 10(-6) cm(2)s(-1), with no metabolic consumption). Coadministration of SR 4317 (1 mmol/kg) with TPZ at a subtherapeutic dose (0.133 mmol/kg) significantly enhanced hypoxic cell killing in HT29 tumor xenografts without causing oxic cell killing, and the combination at its maximum tolerated dose was less toxic to hypoxic cells in the retina than was TPZ alone at its maximum tolerated dose. This study demonstrates that benzotriazine mono-N-oxides have potential use for improving the therapeutic utility of TPZ as a hypoxic cytotoxin in cancer treatment.
authors.affiliation: Auckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand.
authors.forename: Bronwyn G
authors.initials: BG
authors.lastname: Siim
authors.forename: Frederik B
authors.initials: FB
authors.lastname: Pruijn
authors.forename: Joanna R
authors.initials: JR
authors.lastname: Sturman
authors.forename: Alison
authors.initials: A
authors.lastname: Hogg
authors.forename: Michael P
authors.initials: MP
authors.lastname: Hay
authors.forename: J Martin
authors.initials: JM
authors.lastname: Brown
authors.forename: William R
authors.initials: WR
authors.lastname: Wilson
mesh_terms: D000230:Adenocarcinoma; D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D015687:Cell Hypoxia / Q000187:drug effects*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects*; D003110:Colonic Neoplasms; D004357:Drug Synergism; D005260:Female; D006801:Humans; D008175:Lung Neoplasms; D051379:Mice; D010610:Pharyngeal Neoplasms; D000077704:Tirapazamine; D014227:Triazines / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000633:toxicity*; D002583:Uterine Cervical Neoplasms
chemical_list: D000970:Antineoplastic Agents; D014227:Triazines; D000077704:Tirapazamine; C064275:3-amino-1,2,4-benzotriazine-1-oxide